menu
    • menu
    [{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Wellington Management","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Wellington Management"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MBX 1416","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"MBX 1416","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Deep Track Capital","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ Deep Track Capital"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"MBX 2109","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"MBX Biosciences","amount2":0.19,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"MBX Biosciences \/ J.P. Morgan"}]

    Find Clinical Drug Pipeline Developments & Deals by MBX Biosciences

    Menu

    MBX Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $187.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX Biosciences Closes Upsized IPO, Underwriters Purchase Additional Shares

                            Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $187.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Pricing of Initial Public Offering

                            Details : The proceeds will advance the development of MBX 2109 and MBX 1416, two clinical programs, MBX 4291. MBX 2109 is designed as a potential long-acting hormone replacement therapy for hypoparathyroidism.

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Pricing of Initial Public Offering

                            Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $163.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MBX files for IPO, Seeking Cash to Take Challenger to Ascendis' Yorvipath into Phase 3

                            Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 26, 2024

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial for Hypoparathyroidism

                            Details : MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism.

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $63.5 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            MBX Biosciences Raises $63.5M in Series C to Advance Precision Endocrine Peptide™ Platform

                            Details : The net proceeds from the financing will be used to advance the clinical development of the company's lead product, MBX 2109, which is being evaluated for the treatment of hypoparathyroidism.

                            Brand Name : MBX 2109

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $63.5 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bari...

                            Details : MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypogl...

                            Brand Name : MBX 1416

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 09, 2023

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroi...

                            Details : MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism. It was designed with the company’s novel, proprietary Precision Endocrine Peptide™ (PEP™) platform te...

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 11, 2023

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatr...

                            Details : MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypogl...

                            Brand Name : MBX 1416

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 07, 2023

                            Lead Product(s) : MBX 1416

                            Therapeutic Area : Endocrinology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            MBX Biosciences

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Wellington Management

                            Deal Size : $115.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

                            Details : Proceeds of the financing will support clinical advancement of its lead product candidate, MBX 2109, an investigational long-acting parathyroid hormone peptide prodrug, which is in development for the treatment of hypoparathyroidism and currently in a Ph...

                            Brand Name : MBX 2109

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            November 14, 2022

                            Lead Product(s) : MBX 2109

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Wellington Management

                            Deal Size : $115.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth